Visby Medical, a team I was able to help in their early planning phases for commercialization a couple years ago, has had a run of good news this year. Their product is a tiny molecular testing POCT handheld device. See my September note here.
In April, early in the COVID epidemic, the Stanford spinout raised $70M. In September, they got an FDA EUA for their highly innovative device. In October, they announced an additional $10M from the NIH RADx tech investment fund.
See latest announcement here.
